Medpace Holdings, Inc.
Every calculator, already run for MEDP
Open the full toolkit →You have the numbers on MEDP. Get the argument.
A written report on which of these readings actually decide the outcome for Medpace Holdings, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
14 analysts covering MEDPAnalyst Price Target Disagreement for Medpace Holdings, Inc.
Wall Street's bull case implies +9% from the current price; the bear case implies -45%. A 54% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for MEDP
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Medpace Holdings, Inc.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offer…
MEDP — frequently asked
Is MEDP a buy right now?
Wall Street's consensus rating on Medpace Holdings, Inc. is Hold across 14 analysts, with a mean price target of $637.31 (-5% vs. the current $669.20). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is MEDP overvalued?
MEDP trades at 37.2x trailing earnings, against a DCF fair value of $323 per share. The current price implies 16% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
What is the analyst price target disagreement for Medpace Holdings, Inc.?
Analysts covering Medpace Holdings, Inc. (MEDP) range from a bear-case target of $370.00 to a bull-case high of $730.00, with a mean consensus target of $637.31 across 13 analysts. The spread of $360.00 (54% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Medpace Holdings, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Medpace Holdings, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full MEDP research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Medpace Holdings, Inc., in minutes. 3 free reports included with every account — no credit card required.